Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Is HIMS stock the best buy in March 2026?
07:10am, Tuesday, 10'th Mar 2026
Shares of Hims & Hers Health (NYSE: HIMS) have staged a sharp rebound after drugmaker Novo Nordisk (NYSE: NVO) dropped its lawsuit against the company, removing what many investors considered the bigg
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal
06:05pm, Monday, 09'th Mar 2026
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player's GLP-1 strategy, margins, and legal risk profile.
Hims & Hers: Not Selling Yet
05:51pm, Monday, 09'th Mar 2026
Hims & Hers shares surged over 40% after renewing its partnership with Novo Nordisk to sell GLP-1 weight-loss drugs. The new deal reverses last year's public fallout, restoring a key catalyst for Hims
Hims & Hers Health: The Juice Is Worth The Squeeze
04:35pm, Monday, 09'th Mar 2026
Hims & Hers Health (HIMS) is positioned as a disruptive force in traditional healthcare, leveraging digital-first, direct-to-consumer telehealth solutions. Recent legal and regulatory overhangs have e
Stock Of The Day: Will Hims & Hers Go Into Another Short Squeeze?
03:23pm, Monday, 09'th Mar 2026
The stock is now susceptible to a short squeeze, which occurs when a highly shorted stock has a rapid and large move higher. When the squeeze ends, the stock can crash and end up right back where it w
Hims & Hers Jumps 47% as Novo Nordisk Weighs New Weight-Loss Drug Partnership
01:54pm, Monday, 09'th Mar 2026
Hims and Hers Health (HIMS) shares surged in premarket trading after reports suggested the company may be close to repairing its relationship with Novo Nordisk (N
Hims & Hers stock: why today's gains are unlikely to be sustainable
01:27pm, Monday, 09'th Mar 2026
Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership with the Danish pharma giant – Novo Nordisk (NYSE: NVO). This meteoric run e
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
12:24pm, Monday, 09'th Mar 2026
Hims & Hers' deal with Novo Nordisk removes a major overhang by ending a potential, expensive lawsuit. The agreement should also be a nice revenue growth driver.
Hims & Hers Stock Pops 40%: Everything You Need to Know
11:38am, Monday, 09'th Mar 2026
Novo Nordisk is ending its lawsuit with Hims & Hers and the two have now become partners. Ozempic and Wegovy will both be sold on the Hims & Hers platform at the same low price as other direct provide
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why
11:27am, Monday, 09'th Mar 2026
Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
11:05am, Monday, 09'th Mar 2026
Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker's weight-loss medications Wegovy and Ozempic to Hims & Hers
HIMS Skyrockets on Reported Deal with NVO to Sell GLP-1s
11:00am, Monday, 09'th Mar 2026
Multiple reports state that Hims & Hers (HIMS) will partner with Novo Nordisk (NVO) to sell its GLP-1s through the telehealth company's platform. Marley Kayden covers the twists and turns of this tale
Novo Nordisk drops Him & Hers lawsuit
10:38am, Monday, 09'th Mar 2026
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect t
HIMS Stock Eyes Best Day Ever After Dispute Dissolution
10:35am, Monday, 09'th Mar 2026
Hims & Hers Health Inc (NYSE:HIMS) stock is up more than 35% to trade at $21.27 this morning, on track for its best single-session gain ever, after ending a dispute with Novo Nordisk (NVO).
